Kiniksa Pharmaceuticals, Ltd. provided earnings guidance for the full-year 2022. For the year, the company expects ARCALYST net revenue for the full-year 2022 to be between $115 million and $130 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.05 USD | -0.63% | -3.64% | +8.61% |
05-14 | Transcript : Kiniksa Pharmaceuticals, Ltd. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:40 AM | |
04-23 | Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.61% | 1.35B | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-0.29% | 21.78B | |
-9.28% | 18.09B | |
-41.70% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- KNSA Stock
- News Kiniksa Pharmaceuticals, Ltd.
- Kiniksa Pharmaceuticals, Ltd. Provides Earnings Guidance for the Full-Year 2022